ReViral taps Seth Hetherington to guide upcoming PhIIa; Incyte, Aquinox execs move to AI shop Notable Labs
→ Oxford, England-based vaccine developer Emergex has recruited Big Pharma vet Athanasios Papadopoulos to be its CMO. Jumping from Sanofi — where he helped develop the groundbreaking but ill-fated Dengvaxia — Papadopoulos inherits a universal Flavivirus vaccine candidate now poised for Phase I in H2 2019 and a new R&D facility for Emergex’s synthetic vaccines.
→ ReViral has tapped Seth Hetherington to steer its lead RSV candidate into pediatric Phase IIa trials. As CMO (a role he recently held for seven years at Genocea Biosciences), Hetherington will lead the biotech in navigating a field full of nasty surprises, though ReViral has reasons to be confident given positive results in a previous PhIIa. He will be based in the British company’s US office.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.